Related Experiment Video
Updated: Jan 3, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors
Pushpa Neppala1, Sudeep Banerjee2,3, Paul T Fanta4,5
1UC San Diego School of Medicine, University of California, San Diego, La Jolla, CA, USA.
Abstract:
Gastrointestinal stromal tumors (GISTs) are increasingly recognized as having diverse biology. With the development of tyrosine kinase inhibitors molecularly matched to oncogenic KIT and PDGFRA mutations, GISTs have become a quintessential model for precision oncology. However, about 5-10% of GIST lack these driver mutations and are deficient in succinate dehydrogenase (SDH), an enzyme that converts succinate to fumarate. SDH deficiency leads to accumulation of succinate, an oncometabolite that promotes tumorigenesis. SDH-deficient GISTs are clinically unique in that they generally affect younger patients and are associated with GIST-paraganglioma hereditary syndrome, also known as Carney-Stratakis Syndrome. SDH-deficient GISTs are generally resistant to tyrosine-kinase inhibitors, the standard treatment for advanced or metastatic GIST. Thus, surgical resection is the mainstay of treatment for localized disease, but recurrence is common. Clinical trials are currently underway investigating systemic agents for treatment of advanced SDH-deficient GIST. However, further studies are warranted to improve our understanding of SDH-deficient GIST disease biology, natural history, surgical approaches, and novel therapeutics.
Insights
Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) lack common mutations and resist standard treatments. Further research is crucial for understanding these rare GISTs and developing effective therapies.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Gastrointestinal stromal tumors (GISTs) are a model for precision oncology, typically driven by KIT or PDGFRA mutations.
- A subset of GISTs (5-10%) lacks these drivers and exhibits succinate dehydrogenase (SDH) deficiency.
- SDH deficiency results in oncometabolite accumulation, promoting tumorigenesis.
Purpose of the Study:
- To highlight the unique biology and clinical characteristics of SDH-deficient GISTs.
- To underscore the therapeutic challenges posed by SDH-deficient GISTs.
- To emphasize the need for further research into SDH-deficient GISTs.
Main Methods:
- Review of existing literature on GIST biology, genetics, and treatment resistance.
- Analysis of clinical features distinguishing SDH-deficient GISTs from other GIST subtypes.
- Identification of knowledge gaps in disease biology, natural history, and therapeutic strategies.
Main Results:
- SDH-deficient GISTs affect younger patients and are linked to Carney-Stratakis Syndrome.
- These tumors are generally resistant to tyrosine kinase inhibitors, the standard GIST therapy.
- Surgical resection is primary for localized disease, but recurrence rates are significant.
Conclusions:
- SDH-deficient GISTs represent a distinct subtype with unique clinical and molecular features.
- Current treatments are largely ineffective, necessitating novel therapeutic approaches.
- Further investigation into SDH-deficient GISTs is essential for improving patient outcomes.
